Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2020 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
May 29, 2020 08:30 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders

BOSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
May 28, 2020 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at Jefferies 2020 Virtual Healthcare Conference

BOSTON, May 28, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
May 11, 2020 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference

BOSTON, May 11, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
May 11, 2020 06:30 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million

-- Announced Initiation of Funding from BARDA for All FDA Required Post-Marketing Studies and Security Requirements and U.S. Onshoring of an Additional Manufacturing Supply Chain for...
April 30, 2020 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11, 2020

BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
April 02, 2020 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA• (omadacycline)

BOSTON, April 02, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
April 01, 2020 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA• (omadacycline)

BOSTON, April 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
March 10, 2020 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)

BOSTON, March 10, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
March 02, 2020 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, March 02, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...